SCHEMBL14699620

SCHEMBL14699620

COc1ccc(C(=O)c2ccc(/N=N/N(C)C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RXFP1 Q9HBX9 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ LMNA P02545 2/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ ACHE P22303 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ GAA P10253 1/20 0.49
▸ TUBB4A P04350 1/20 0.47
▸ TUBB P07437 1/20 0.47
▸ TUBA3C P0DPH7 1/20 0.47
▸ TUBA1B P68363 1/20 0.47
▸ TUBA4A P68366 1/20 0.47
▸ TUBB4B P68371 1/20 0.47
▸ TUBB3 Q13509 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38787 1.00 MAPT (0.55) MAPTRAB9ANPC1RXFP1HPGD
SCHEMBL47175 0.83 MAPT (0.62) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL14699614 0.82 MAPT (0.50) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL26771623 0.82 MAPT (0.50) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL17988686 0.82 MAPT (0.50) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL12817727 0.81 MAPT (0.55) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL17988727 0.81 ALDH1A1 (0.61) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL14699617 0.81 MAPT (0.55) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL14699621 0.81 RAB9A (0.55) MAPTRAB9ANPC1HPGDLMNA
SCHEMBL14699619 0.81 MAPT (0.55) MAPTRAB9ANPC1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2023-11-09 — — US disclosed
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2023-11-09 — — US disclosed
WO-2022063549-A1 ACTIVE SUBSTANCES AND DRUGS FOR THERAPY OF VIRAL DISEASES, PARTICULARLY CORONA INFECTIONS, MORE PARTICULARLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2022-03-31 — — WO disclosed
EP-2557075-A1 New triazene compounds for treating cancer Trin Therapeutics GmbH (DE) 2013-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 ACE, ACE2, SARS1 MAPT 847/4885RAB9A 2059/4885NPC1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback